ESPEN LLL Course Topic 23 - Nutrition in Obesity





THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

Obesity Aetiopathogenesis and Complications

Module 23.1

Rocco Barazzoni


Department of Medical, Surgical and Health Sciences University of Trieste - Italy

01.09.2019





THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM








OVERWEIGHT and OBESITY

"Chronic conditions characterized by abnormalexcess fat accumulation leading to excess morbidity" (WHO)

Clinical = $BMI > 30 \text{ kg/m}^2$













Outline

THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM


- Energy intake (Appetite regulation)

- Energy expenditure (Intermediate metabolism)
- Clinical impact of obesity
- Malnutrition in obesity (?)














THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

GUT ENDOCRINE SYSTEM Nutrient-inggered SAITE







THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

GUT ENDOCRINE SYSTEM



Substrates (Glucose, **Food Intake** FA) **Gastric Emptying Incretins GIP-**GLP1 Insulin Secretion Insulin **HIGH-FAT DIET** OXM SATIETY PYY RESISTANCE **CCK-PP**

ESPEN LLL Programme

Education and Culture DG

Lifelong Learning Programme






Leptin resistance in diet-induced obesity: the role of hypothalamic inflammation


De Git et al, Obesity Rev 2015


THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION A


METABOLISM (a) Short-term HFD-feeding



(b) Chronic HFD-feeding













- Food intake regulation is complex and only partly understood
- Appetite regulation is at least partly beyond volitional control
- Failure of homeostatic feedback control mechanisms in the presence of food availability favours the obesity epidemic and likely reflects evolutionary processes





Outline


THE EUROPEAN
SOCIETY
FOR CLINICAL
NUTRITION AND
METABOLISM

- Energy intake (Appetite regulation)
- <u>Energy expenditure</u> (Intermediate metabolism)
- Clinical impact of obesity
- Malnutrition in obesity (?)

Physical activity and weight gain during high-fat diet



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM




Prentice et al, Nutr Rev 2004











OBESE and Sedentary





ESPEN

	· · · ·	· · · · · · · · · · · ·		
	Walking bouts (n/day)	Time engaged in walking (minutes/day)	Average distance of a walking bout (miles)	Free-living walking velocity (mph)
Baseline				
Lean	46 ± 8	448 ± 111	0.22 ± 0.04	1.19 ± 0.21
Obese	47 ± 5	$339 \pm 74^*$	0.14 ± 0.04 †	1.10 ± 0.20
Total	47 ± 6	389 ± 106	0.18 ± 0.06	1.14 ± 0.20
Overfed				
Lean	48 ± 11	459 ± 119	$0.19 \pm 0.06 \ddagger$	1.09 ± 0.28
Obese	47 ± 9	$334 \pm 79^{*}$	0.11 ± 0.03 §¶	0.96 ± 0.15
Total	47 ± 10	391 ± 116	$0.15 \pm 0.06^{**}$	1.02 ± 0.20**

Levine et al, Diabetes 2008

Being obese is associated with negative changes in QUANTITY and QUALITY of walking during overfeeding (VICIOUS CYCLING)

REGULATION LARGELY UNKNOWN!! (GENETIC-VOLITIONAL-ENDOCRINE/METABOLIC?)







Clinical impact of obesity


个个个 ACUTE and CHRONIC DISEASE

Towards a multidisciplinary approach to understand and manage obesity and related diseases*

Stephan C. Bischoff^{a,*}, Yves Boirie^b, Tommy Cederholm^c, Michael Chourdakis^d, Cristina Cuerda^e, Nathalie M. Delzenne^f, Nicolaas E. Deutz^g, Denis Fouque^h, Laurence Genton¹, Carmen Gil¹, Berthold Koletzko^k, Miguel Leon-Sanz¹, Raanan Shamir^m, Joelle Singer^{n, o}, Pierre Singer^{o, p}, Nanette Stroebele-Benschop^q, Anders Thorell¹, Arved Weimann⁵, Rocco Barazzoni




THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM



CHF

Lavie et al, JACC 2009



CANCER

Nature Reviews | Cancer







↑↑↑ (CARDIO)METABOLIC COMPLICATIONS


THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

INSULIN RESISTANCE

METABOLIC SYNDROME

TYPE 2 DIABETES

CARDIOVASCULAR DISEASE









THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM




Dealing with excess fat


ADIPOSOPATHY






Paglialunga S et al, Diabetologia 2015











Consensus criteria of the Metabolic Syndrome IDF-AHA/NHLBI

THE EUROPEAN SOCIETY FOR CLINI NUTRITIO METABOLI

FOR CLINICAL	Measure		Categorical cut points		
METABOLISM	 Elevated waist 		Variable according to ETHNICITY		
	• Elevated	d blood pressure**	Systolic > 130 and/or diastolic > 85 mm Hg		
	 Elevated fasting glucose** 		<u>≥</u> 100 mg/dl		
	 Elevated triglycerides** 		≥ 150 mg/dl (1.7 mmol/L)		
Reduced HDL-c**		d HDL-c**	< 40 mg/dl (1.0 mmol/L) in males; < 50 mg/dl (1.3 mmol/L) in females		
**or d	Irug	Any 3 o	of 5 risk factors		
treatn	nent	constitutes	a diagnosis of MS		
		Alberti KGMM, et al. Ci	rculation 2009; 120: 1640-5.		

ESPEN MetS and CVD





THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

Study	Population	n/N	n/N	RR (log s	cale)	95% CI
		96/5,595	118/15,194			2.19 (1.67 to 2.86)
		27/1,792	51/7,256		-	2.14 (1.35 to 3.41)
Katzmarzyk 2005	Healthy weight men	7/352	38/7,153			3.74 (1.68 to 8.32)
Butler 2005	General population	60/1,169	70/1,866			1.37 (0.98 to 1.92)
Lee 2008	Women	27/622	16/2.290			6.21 (3.37 to 11.46)
Thomas 2007	General population	17/502	13/2,348			6.12 (2.99 to 12.51)
DECODE study 2007	Men without T2DM aged 50-69	41/739	77/2,051		-	1.48 (1.02 to 2.14)
Lee 2008	Men	55/677	30/2,110			5.71 (3.69 to 8.84)
Katzmarzyk 2005	Obese men	25/1,601	12/1,019	-	•	1.33 (0.67 to 2.63)
Hunt 2007	Women without T2DM	20/395	32/2,137	g		3.38 (1.95 to 5.85)
Langenberg 2006	General population	128/337	519/1,781	Shudies		1.3 (1.12 to 1.52)
Mancia 2006	General population	24/327	41/,1686			3.02 (1.85 to 4.92)
Hunt 2007	Men without T2DM	27/376	62/1,584			1.81 (1.17 to 2.81)
Nev a 2007	Viomen	1/22	25/1,230			2.24 (0.32 to 15.78)
Niw a 2007	Man	5/82	28/832	_		1.81 (0.72 to 4.57)
Espinola-Klein 2007	Pts with CAD	64/349	34/462			2.49 (1.68 to 3.69)
Kasai 2006	Pts who underwent PCI	20/318	10/430			2.7 (1.28 to 5.7)
Noto 2008	General population	15/142	38/490	-		1.36 (0.77 to 2.4)
Chen 2005	Pts with renal disease and ACS	12/51	0/18			9.13 (0.57 to 146.86)
TOTAL:		670/15,448	1,214/51,917		\diamond	2.4 (1.87 to 3.08)
				0.1	10	100
				Decreased risk	hcreased risk	
_						


Mottillo et al, JACC 2010






Outline


- Energy intake (Appetite regulation)
- Energy expenditure (Intermediate metabolism)
- Clinical impact of obesity
- Malnutrition in obesity (?)



ESPEN Impaired BAT activity in OBESITY!







Insulin Resistance






Outline

- Energy intake (Appetite regulation)
- Energy expenditure (Intermediate metabolism)
- Clinical impact of obesity
- Malnutrition in obesity (?)







THERAPEUTIC WEIGHT LOSS BARIATRIC SURGERY


Elbow joint



THE EUROPEAN SOCIETY

FOR CLINICAL

METABOLISM



Origins from scapula Scapula -Shoulder join MASS Triceps mu **FUNCTION** Tendon insertion on uina

Insertion on radius

Redus



BEYOND BMI ONE OBESITY SIZE does NOT FIT ALL!




THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

Body Composition (FAT/MUSCLE)

- SARCOPÉNIC OBESITY

- ↑ FRAILTY-MORBIDITY
 - ↑ MORTALITY

Obesity leads to higher chance of disability than other major disease risk factors



ESPEN endorsed recommendation

Sarcopenic obesity: Time to meet the challenge

Rocco Barazzoni^{a, b, *}, Stephan C. Bischoff^c, Yves Boirie^{d, e}, Luca Busetto^{f, g}, Tommy Cederholm^h, Dror Dickerⁱ, Hermann Toplak^j, Andre Van Gossum^k, Volkan Yumuk¹, Roberto Vettor^{f, g}

Clin Nutr 2018


ESPEN Obese AND Malnourished





GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community $\hat{\pi}$

THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM T. Cederholm ^{a, b, *, 1}, G.L. Jensen ^{c, 1}, M.I.T.D. Correia ^d, M.C. Gonzalez ^e, R. Fukushima ^f, T. Higashiguchi ^g, G. Baptista ^h, R. Barazzoni ⁱ, R. Blaauw ^j, A. Coats ^{k, 1}, A. Crivelli ^m, D.C. Evans ⁿ, L. Gramlich ^o, V. Fuchs-Tarlovsky ^p, H. Keller ^q, L. Llido ^r, A. Malone ^{s, t}, K.M. Mogensen ^u, J.E. Morley ^v, M. Muscaritoli ^w, I. Nyulasi ^x, M. Pirlich ^y, V. Pisprasert ^z, M.A.E. de van der Schueren ^{aa, ab}, S. Siltharm ^{ac}, P. Singer ^{ad, ae}, K. Tappenden ^{af}, N. Velasco ^{ag}, D. Waitzberg ^{ah}, P. Yamwong ^{ai}, J. Yu ^{aj}, A. Van Gossum ^{ak, 2}. C. Compher ^{al, 2}. GLIM Core Leadership Committee, GLIM Working Group³ Risk screening





THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

ESPEN guideline on clinical nutrition in the intensive care unit

Pierre Singer ^{a, *}, Annika Reintam Blaser ^{b, c}, Mette M. Berger ^d, Waleed Alhazzani ^e, Philip C. Calder ^f, Michael P. Casaer ^g, Michael Hiesmayr ^h, Konstantin Mayer ⁱ, Juan Carlos Montejo ^j, Claude Pichard ^k, Jean-Charles Preiser ¹, Arthur R.H. van Zanten ^m, Simon Oczkowski ^e, Wojciech Szczeklik ⁿ, Stephan C. Bischoff ^o


Clin Nutr 2018

Recommendations 51-52

An iso-caloric high protein diet can be administered to obese patients, preferentially guided by indirect calorimetry measurements and urinary nitrogen losses.

Grade of recommendation: 0 - consensus (89% agreement)

If urinary nitrogen losses or lean body mass determination are not available, protein intake can be 1.3 g/kg "adjusted body weight"/d.



PROTEIN: 1.3 g/kg ABW (=1.6-1.8 g/kg IBW)



Conclusions





- Actiology and pathogenesis of obesity involve lifestyle changes that however appear to be only partly under volitional control
- Their negative impact on body fat accumulation is moreover largely influenced by genetic, epigenetic and metabolic factors
- Clinical complications of obesity potentially involve all organs and systems with a relevant role for insulin resistance and its cardio-metabolic impact
- Clinical complications of obesity include malnutrition with a major role for skeletal muscle loss of mass and function (sarcopenic obesity)